TY - JOUR AU - Hede, K. PY - 2008 DA - 2008// TI - Superhighway or blind alley? The cancer genome atlas releases first results JO - J Natl Cancer Inst VL - 100 UR - https://doi.org/10.1093/jnci/djn424 DO - 10.1093/jnci/djn424 ID - Hede2008 ER - TY - JOUR AU - Demetri, G. D. PY - 2002 DA - 2002// TI - Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571) JO - Eur J Cancer VL - 38 UR - https://doi.org/10.1016/S0959-8049(02)80603-7 DO - 10.1016/S0959-8049(02)80603-7 ID - Demetri2002 ER - TY - JOUR AU - Bollag, G. AU - Hirth, P. AU - Tsai, J. PY - 2010 DA - 2010// TI - Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma JO - Nature VL - 467 UR - https://doi.org/10.1038/nature09454 DO - 10.1038/nature09454 ID - Bollag2010 ER - TY - JOUR AU - Flaherty, K. T. AU - Puzanov, I. AU - Kim, K. B. PY - 2010 DA - 2010// TI - Inhibition of mutated, activated BRAF in metastatic melanoma JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1002011 DO - 10.1056/NEJMoa1002011 ID - Flaherty2010 ER - TY - JOUR AU - Abbeele, A. D. AU - Badawi, R. D. PY - 2002 DA - 2002// TI - Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs) JO - Eur J Cancer VL - 38 UR - https://doi.org/10.1016/S0959-8049(02)80604-9 DO - 10.1016/S0959-8049(02)80604-9 ID - Abbeele2002 ER - TY - JOUR AU - McArthur, G. A. AU - Puzanov, I. AU - Amaravadi, R. PY - 2012 DA - 2012// TI - Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.39.1938 DO - 10.1200/JCO.2011.39.1938 ID - McArthur2012 ER - TY - JOUR AU - Parmenter, T. J. AU - Kleinschmidt, M. AU - Kinross, K. M. PY - 2014 DA - 2014// TI - Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis JO - Cancer Discov VL - 4 UR - https://doi.org/10.1158/2159-8290.CD-13-0440 DO - 10.1158/2159-8290.CD-13-0440 ID - Parmenter2014 ER - TY - JOUR AU - Hanahan, D. AU - Weinberg, R. A. PY - 2011 DA - 2011// TI - Hallmarks of cancer: the next generation JO - Cell VL - 144 UR - https://doi.org/10.1016/j.cell.2011.02.013 DO - 10.1016/j.cell.2011.02.013 ID - Hanahan2011 ER - TY - JOUR AU - Smyth, M. J. AU - Dunn, G. P. AU - Schreiber, R. D. PY - 2006 DA - 2006// TI - Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity JO - Adv Immunol VL - 90 UR - https://doi.org/10.1016/S0065-2776(06)90001-7 DO - 10.1016/S0065-2776(06)90001-7 ID - Smyth2006 ER - TY - JOUR AU - Fridman, W. H. AU - Zitvogel, L. AU - Sautès-Fridman, C. AU - Kroemer, G. PY - 2017 DA - 2017// TI - The immune contexture in cancer prognosis and treatment JO - Nat Rev Clin Oncol VL - 14 UR - https://doi.org/10.1038/nrclinonc.2017.101 DO - 10.1038/nrclinonc.2017.101 ID - Fridman2017 ER - TY - JOUR AU - Wong, A. N. AU - McArthur, G. A. AU - Hofman, M. S. AU - Hicks, R. J. PY - 2017 DA - 2017// TI - The advantages and challenges of using FDG PET/CT for response assessment in melanoma in the era of targeted agents and immunotherapy JO - Eur J Nucl Med Mol Imaging VL - 44 UR - https://doi.org/10.1007/s00259-017-3691-7 DO - 10.1007/s00259-017-3691-7 ID - Wong2017 ER - TY - JOUR AU - Hicks, R. J. PY - 2016 DA - 2016// TI - How I read cancer imaging studies: the master class series JO - Cancer Imaging VL - 16 UR - https://doi.org/10.1186/s40644-016-0067-3 DO - 10.1186/s40644-016-0067-3 ID - Hicks2016 ER -